GlassScriptPhysician profile
Jamison M Hofer
NPI 1306208814
$4,827.58
in general payments reported to CMS, 2019-2025
44 companies · $2,468 in 2025
The $2,468 reported for 2025 was more than what 76% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $126 · 2021: $34.14 · 2022: $121 · 2023: $139 · 2024: $1,940 · 2025: $2,468.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,842 · Education: $705.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,841.57 |
| Education | $705.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $708.58 | 2023-2025 | |
| Abbvie INC. | $601.86 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $329.08 | 2024-2025 | Austedo Xr, Austedo Xr |
| Ipsen Biopharmaceuticals, INC | $276.11 | 2019-2025 | Dysport |
| Boston Scientific Corporation | $219.38 | 2024-2025 | Watchman Flx, Vercise |
| Celgene Corporation | $216.54 | 2024-2025 | Zeposia |
| Novartis Pharmaceuticals Corporation | $198.48 | 2024-2025 | |
| Lilly USA, LLC | $179.52 | 2024-2025 | Emgality, Kisunla |
| Neurocrine Biosciences, INC. | $172.09 | 2024-2025 | Ingrezza |
| Argenx US, INC. | $152.40 | 2024-2025 | Vyvgart Hytrulo |
| Janssen Biotech, INC. | $116.94 | 2025 | |
| Biogen, INC. | $112.60 | 2024-2025 | Vumerity, Tysabri, Spinraza |
| Emd Serono, INC. | $99.18 | 2024-2025 | |
| Hospira, INC. | $92.79 | 2025 | |
| Acadia Pharmaceuticals INC | $92.18 | 2024 | Nuplazid |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $89.72 | 2024-2025 | |
| Lundbeck LLC | $85.41 | 2025 | Vyepti |
| Axsome Therapeutics, INC. | $80.48 | 2025 | Symbravo, Sunosi |
| Csl Behring | $74.47 | 2024-2025 | Hizentra |
| Neurelis, INC. | $73.63 | 2024-2025 | Valtoco |
| Genzyme Corporation | $73.52 | 2024-2025 | |
| Tg Therapeutics, INC. | $68.33 | 2025 | |
| Jazz Pharmaceuticals INC. | $65.24 | 2025 | |
| Livanova USA, INC. | $58.84 | 2024-2025 | Vns Therapy Sentiva Model 1000 Generator, Vns Therapy |
| Astrazeneca Pharmaceuticals LP | $54.07 | 2023-2025 | Wainua |
| Genentech USA, INC. | $53.60 | 2025 | Ocrevus Zunovo |
| Eisai INC. | $50.48 | 2025 | |
| Octapharma USA, INC. | $46.44 | 2024-2025 | Panzyga, Octagam Immune Globulin (Human) |
| Amgen INC. | $46.01 | 2024-2025 | Aimovig, Uplizna |
| Ucb, INC. | $42.37 | 2024 | Rystiggo, Briviact |
| Merz Pharmaceuticals, LLC | $36.29 | 2025 | Inbrija, Xeomin |
| Ani Pharmaceuticals, INC. | $27.84 | 2024 | Purified Cortrophin Gel |
| Mdd US Operations, LLC | $24.90 | 2025 | Gocovri |
| Takeda Pharmaceuticals U.S.A., INC. | $24.64 | 2024 | Hyqvia |
| Kyowa Kirin, INC. | $24.60 | 2024 | Nourianz |
| Aurinia Pharma U.S., INC. | $22.01 | 2022 | |
| Impel Pharmaceuticals LLC | $21.54 | 2025 | Trudhesa |
| Biohaven Pharmaceuticals, INC. | $20.44 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.62 | 2022 | |
| Mallinckrodt Hospital Products INC. | $17.14 | 2024 | Acthar |
| Alexion Pharmaceuticals, INC. | $16.39 | 2022 | |
| Catalyst Pharmaceuticals, INC. | $14.64 | 2025 | |
| Corcept Therapeutics | $13.70 | 2021 | |
| Allergan, INC. | $13.49 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamison Hofer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.